© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
December 01, 2021
Underlying autoimmune disease alters uveitis therapy.
November 05, 2021
A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.
October 31, 2021
The investigators reported the following most prominent cognitive deficits: processing speed, executive functioning, and phonemic fluency among others.
October 27, 2021
XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable safety profile.
October 10, 2021
During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.
October 10, 2021
At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.
September 08, 2021
Investigators have found that 1 intravitreal injection of an adeno-associated virus encoding an immunosuppressive transgene, either HLA-G or eqIL-10, reduced the clinical and histologic inflammation in a well-established model of autoimmune uveitis.
August 05, 2021
The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.
July 21, 2021
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
July 06, 2021
Investigators found that 56.4% of Horner’s syndrome cases resulted from a dangerous cause.